Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Classical hematology 1Breast 1

Conditions

Breast Neoplasms 19Neutropenia 13Hodgkin Disease 5Lymphoma 4Lymphoma, Large B-Cell, Diffuse 3Chemotherapy-induced Neutropenia 3Triple Negative Breast Neoplasms 2Febrile Neutropenia 2Dendritic Cell Sarcoma, Interdigitating 2Carcinoma, Non-Small-Cell Lung 2Breast Neoplasms, Male 2Sarcoma, Synovial 1Sarcoma 1Rhabdomyosarcoma 1Recurrent Uterine Corpus Carcinoma 1Rectal Neoplasms 1Neurofibrosarcoma 1Neoplasms, Germ Cell and Embryonal 1Neoplasms 1Neoplasm Metastasis 1Multiple Myeloma 1Lung Neoplasms 1Liposarcoma 1Leiomyosarcoma 1Histiocytoma, Malignant Fibrous 1Hemangiosarcoma 1Heart Failure 1Fibrosarcoma 1Fever 1Endometrial Adenocarcinoma 1

Interventions

pegfilgrastim 1MYL-1401H 1Long-Term Synaptic Depression 1Granulocyte Colony-Stimulating Factor 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Chemotherapy-Induced Febrile Neutropenia × pegfilgrastim × Clear all
NCT02467868 2022-02-14

Efficacy and Safety Study With MYL-1401H and Neulasta

Viatris Inc.

Phase 3 Completed
193 enrolled
BreastClassical hematology

Breast Neoplasms, Neutropenia, Chemotherapy-Induced Febrile Neutropenia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡